motor neuron disease/диария

Линкът е запазен в клипборда

СтатииКлинични изследванияПатенти

Изберете тип сортиране

13 резултата

Riluzole: a new agent for amyotrophic lateral sclerosis.

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

OBJECTIVE To provide a comprehensive review of riluzole, including its mechanism of action, pharmacokinetics, adverse drug reactions, drug interactions, efficacy, and administration. A brief review of amyotrophic lateral sclerosis (ALS) is also included. METHODS A computerized search of the MEDLINE

Survey of current enteral nutrition practices in treatment of amyotrophic lateral sclerosis.

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

OBJECTIVE Enteral nutrition (EN) is commonly prescribed for dysphagia and weight loss in amyotrophic lateral sclerosis (ALS), but there are currently no ALS-specific EN guidelines. We aimed to survey current practices prescribing EN to ALS patients. METHODS An online survey was distributed using

A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis.

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

OBJECTIVE To determine if long-term topiramate therapy is safe and slows disease progression in patients with ALS. METHODS A double-blind, placebo-controlled, multicenter randomized clinical trial was conducted. Participants with ALS (n = 296) were randomized (2:1) to receive topiramate (maximum

[Amyotrophyc lateral sclerosis; gastrointestinal complications in home enteral nutrition].

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

OBJECTIVE To analyze the complications related to enteral nutritional support in patients with lateral amyotrophic sclerosis included in our home-based mechanical ventilation program (HMVP), with a special emphasis on gastrointestinal complications. METHODS Retrospective, descriptive study of the

An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions.

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

BACKGROUND Pseudobulbar affect (PBA) is associated with neurological disorders or injury affecting the brain, and characterized by frequent, uncontrollable episodes of crying and/or laughing that are exaggerated or unrelated to the patient's emotional state. Clinical trials establishing

Dextromethorphan/Quinidine for Pseudobulbar Affect Following Stroke: Safety and Effectiveness in the PRISM II Trial.

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

BACKGROUND Dextromethorphan (DM) / quinidine (Q) was approved for pseudobulbar affect (PBA) treatment based on efficacy and safety trials in patients with PBA caused by amyotrophic lateral sclerosis or multiple sclerosis. The PRISM II trial evaluated DM/Q as PBA treatment in patients with stroke,

PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury.

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

BACKGROUND Phase 3 trials supporting dextromethorphan/quinidine (DM/Q) use as a treatment for pseudobulbar affect (PBA) were conducted in patients with amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS). The PRISM II study provides additional DM/Q experience with PBA secondary to

Safety, Tolerability, and Effectiveness of Dextromethorphan/Quinidine for Pseudobulbar Affect Among Study Participants With Traumatic Brain Injury: Results From the PRISM-II Open Label Study.

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

BACKGROUND Dextromethorphan 20 mg / quinidine 10 mg (DM/Q) was approved to treat pseudobulbar affect (PBA) based on phase 3 trials conducted in participants with amyotrophic lateral sclerosis or multiple sclerosis. PRISM II evaluated DM/Q effectiveness, safety, and tolerability for PBA following

Report of a novel ATP7A mutation causing distal motor neuropathy.

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

We describe a novel ATP7A gene mutation associated with distal motor neuropathy, mild connective tissue abnormalities and autonomic disturbances. Next-generation sequencing analysis of a lower-motor neuron diseases gene panel was performed in two sibs presenting with distal motor neuropathy plus an

[An acute axonal form of Guillain-Barré syndrome with antibodies against gangliosides GM1 and GD1b--a case report].

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

We reported a case of Guillain-Barré syndrome with autoantibodies against gangliosides GM1 and GD1b, which has not been reported yet. A 25-year-old man was admitted with a 7-day history of acute progressive weakness in the extremities. Two weeks before admission he had suffered from an episode of

[Tolerability of riluzole: a review of the literature].

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease with the fatal evolution. Recent studies in knowledge of the pathogenic mechanisms underlying ALS showed that the excitotoxicity has an important role in the neurodegeneration. The riluzole, an antagonist of glutamate, is

The Gastric Bypass for Failed Bariatric Surgical Procedures.

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

METHODS: Evaluated are surgical difficulties, management problems and weight loss in patients with distal gastric bypass as a revisionary procedure. Eighty patients were followed up to 3 years; four were lost to follow-up. Mean age was 43; mean prebariatric surgery weight 134 kg; height 1.65 meters;

An open-label study to assess safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in dementia: PRISM II results.

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

Dextromethorphan (DM)/quinidine (Q) is an approved treatment for pseudobulbar affect (PBA) based on trials in amyotrophic lateral sclerosis or multiple sclerosis. PRISM II evaluated DM/Q effectiveness and tolerability for PBA secondary to dementia, stroke, or traumatic brain injury; dementia cohort

Присъединете се към нашата
страница във facebook

Herbal & Natural Medicine

Най-пълната база данни за лечебни билки, подкрепена от науката

Работи на 55 езика
Билкови лекове, подкрепени от науката
Разпознаване на билки по изображение
Интерактивна GPS карта - маркирайте билките на място (очаквайте скоро)
Прочетете научни публикации, свързани с вашето търсене
Търсете лечебни билки по техните ефекти
Организирайте вашите интереси и бъдете в крак с научните статии, клиничните изследвания и патентите

Въведете симптом или болест и прочетете за билките, които биха могли да помогнат, напишете билка и вижте болестите и симптомите, срещу които се използва.
* Цялата информация се базира на публикувани научни изследвания